# US 2026/0027233 A1 · Gja1-20k compositions and methods for mitigating ischemia-reperfusion injury

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0027233 A1
- Document ID: US20260027233A1
- Status: Published application
- Kind: A1
- Application number: 18/998,041
- Filed: 2023-08-31
- Published: 2026-01-29
- Earliest claimed: 2022-08-31
- Applicants: University of Utah Research Foundation
- Inventors: Guillaume Hoareau; Robin M. Shaw
- Web page: https://patentgrep.com/patent/US20260027233A1

## CPC

- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 38/177: {Receptors; Cell surface antigens; Cell surface determinants}
- A61K 48/0075: {characterised by an aspect of the delivery route, e.g. oral, subcutaneous}
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C07K 14/4702: {Regulators; Modulating activity}
- C12N 15/86: Viral vectors
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2319/20: containing a tag with affinity for a non-protein ligand
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Described herein are compositions and methods for treating, preventing, reducing the likelihood of having, reducing the severity of and/or slowing the progression of ischemia-reperfusion injury in a subject using GJA1-20k as a therapeutic agent. In one embodiment, the compositions and methods comprise a GJA1-20k peptide therapy. In another embodiment, the compositions and methods comprise a GJA1-20k gene therapy. In some embodiments, the GJA1-20k therapy comprises truncated forms of GJA1-20k. In some embodiments, the GJA1-20k therapy mitigates mitochondrial stress and dysfunction.

## Claims

### Claim 1

A method of treating, preventing, reducing the likelihood of having, reducing the severity of, and/or slowing the progression of ischemia-reperfusion injury in a subject, the method comprising:
administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising:
a GJA1-20k polypeptide or functional variant or fragment thereof; or
a GJA1-20k gene expression vector comprising a polynucleotide sequence encoding a GJA1-20k polypeptide or functional variant or fragment thereof.

### Claim 2 (depends on 1)

The method of claim 1, wherein the pharmaceutical composition is administered to the subject by intravenous (IV) injection.

### Claim 3 (depends on 1)

The method of claim 1, wherein the GJA1-20k polypeptide or functional variant or fragment thereof comprises an amino acid sequence having at least 90-99% identity to any one of SEQ ID NO: 1 or 3, or an amino acid sequence that is encoded by a polynucleotide having 90-99% identity to SEQ ID NO: 4.

### Claim 4 (depends on 1)

The method of claim 1, wherein the GJA1-20k polypeptide or functional variant or fragment thereof comprises an amino acid sequence selected from any one of SEQ ID NO: 1 or 3, or an amino acid sequence that is encoded by SEQ ID NO: 4.

### Claim 5 (depends on 1)

The method of claim 1, wherein the GJA1-20k polypeptide or functional variant or fragment thereof further comprises a polyaspartate (D10) peptide tag (SEQ ID NO: 2).

### Claim at position 6

6-7. (canceled)

### Claim 8 (depends on 1)

The method of claim 1, wherein the GJA1-20k gene expression vector is selected from a viral vector, an adeno-associated virus (AAV) vector, a recombinant AAV (rAAV) vector, a single-stranded AAV vector, a double-stranded AAV vector, a self-complementary AAV (scAAV) vector, or combinations thereof.

### Claim 9 (depends on 8)

The method of claim 8, wherein the GJA1-20k gene expression vector is an AAV vector of a serotype selected from AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, or a hybrid serotype thereof.

### Claim 10 (depends on 9)

The method of claim 9, wherein the GJA1-20k gene expression vector is an AAV9 vector.

### Claim 11 (depends on 1)

The method of claim 1, wherein the ischemia-reperfusion injury in the subject is the result of severe bleeding, hemorrhagic or hypovolemic shock, resuscitative endovascular balloon occlusion of the aorta, solid organ transplant, cardiac bypass surgery, cardiac angioplasty, radio-opaque dye injury to kidneys, damage to downstream organs in vascular surgery, or combinations thereof.

### Claim 12

A pharmaceutical composition comprising a GJA1-20k polypeptide or functional variant or fragment thereof.

### Claim 13 (depends on 12)

The pharmaceutical composition of claim 12, wherein the GJA1-20k polypeptide or functional variant or fragment thereof comprises an amino acid sequence having at least 90-99% identity to any one of SEQ ID NO: 1 or 3.

### Claim 14 (depends on 12)

The pharmaceutical composition of claim 12, wherein the GJA1-20k polypeptide or functional variant or fragment thereof comprises an amino acid sequence selected from any one of SEQ ID NO: 1 or 3.

### Claim 15 (depends on 12)

The pharmaceutical composition of claim 12, wherein the GJA1-20k polypeptide or functional variant or fragment thereof further comprises a polyaspartate (D10) peptide tag (SEQ ID NO: 2).

### Claim 16

A pharmaceutical composition comprising a GJA1-20k gene expression vector comprising a polynucleotide sequence encoding a GJA1-20k polypeptide or functional variant or fragment thereof.

### Claim 17 (depends on 16)

The pharmaceutical composition of claim 16, wherein the polynucleotide sequence has at least 90-99% identity to SEQ ID NO: 4.

### Claim 18 (depends on 16)

The pharmaceutical composition of claim 16, wherein the polynucleotide sequence is SEQ ID NO: 4.

### Claim 19 (depends on 16)

The pharmaceutical composition of claim 16, wherein the GJA1-20k gene expression vector is selected from a viral vector, an adeno-associated virus (AAV) vector, a recombinant AAV (rAAV) vector, a single-stranded AAV vector, a double-stranded AAV vector, a self-complementary AAV (scAAV) vector, or combinations thereof.

### Claim 20 (depends on 19)

The pharmaceutical composition of claim 19, wherein the GJA1-20k gene expression vector is an AAV vector of a serotype selected from AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, or a hybrid serotype thereof.

### Claim 21 (depends on 20)

The pharmaceutical composition of claim 20, wherein the GJA1-20k gene expression vector is an AAV9 vector.

### Claim at position 21

22-25. (canceled)
